Ataluren + PLACEBO
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Muscular Dystrophy, Duchenne
Conditions
Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Trial Timeline
Jul 6, 2017 → Jul 25, 2023
NCT ID
NCT03179631About Ataluren + PLACEBO
Ataluren + PLACEBO is a phase 3 stage product being developed by PTC Therapeutics for Muscular Dystrophy, Duchenne. The current trial status is completed. This product is registered under clinical trial identifier NCT03179631. Target conditions include Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03179631 | Phase 3 | Completed |
| NCT02758626 | Phase 2 | Completed |
| NCT02647359 | Phase 2 | Completed |
| NCT01826487 | Phase 3 | Completed |
| NCT00803205 | Phase 3 | Completed |
| NCT00592553 | Phase 2 | Completed |
Competing Products
20 competing products in Muscular Dystrophy, Duchenne